Abiomed, part of Johnson & Johnson MedTech, is a leading provider of medical technology known for its innovative products that provide circulatory support and oxygenation. One of their groundbreaking products is Impella, which has been proven to be highly effective during high-risk percutaneous coronary intervention (PCI) procedures. A recent third-party analysis showcased that utilizing Impella during these procedures can lead to a more complete revascularization compared to the traditional intra-aortic balloon pump (IABP) support.

This means that physicians can achieve better outcomes and potentially improve long-term patient survival. The analysis also revealed that a more complete revascularization can result in a greater reduction in heart failure and angina symptoms, as well as an improved quality of life for the patient. Abiomed's commitment to research and innovation ensures that they continue to develop cutting-edge technologies to enhance patient outcomes and revolutionize the field of cardiovascular interventions